

SOLUBILITY SCREENING BY UPLC/MS/MS

Darcy Shave and Pete Alden
Waters Corporation, Milford, MA, U.S.A.

INTRODUCTION

Determining solubility has become an essential step in the early stages of the drug discovery process. Solubility is important because the ratio of the anticipated dose of a given drug to its solubility, together with the dissolution rate, determine the fraction of the dose available for absorption. Because gastric and intestinal fluids are a complex mixture of natural surfactants, salts, and buffers, it is also important to determine the effect of pH, salts, and surfactants on a drug's solubility.

Potentiometric titration and nephelometry are two popular methods for the fast determination of drug solubility. While these methods may be high throughput, the solubility range is limited by the sensitivity of the detection methods and the concentration of the stock DMSO solutions.

Results obtained via these methods are also less reliable for designing in vivo animal toxicity and drug metabolism and pharmacokinetics (DMPK) studies, in which solubilization of the drug substance in proper media is often required to prepare liquid formulations at various concentrations.

UltraPerformance LC® (UPLC®) technology can be used to measure compound solubility in either an aqueous buffer solution or mixtures of co-solvents with relatively high-throughput capability, while maintaining adequate accuracy of results.

Given the selectivity and sensitivity of MS/MS detection, UPLC/MS/MS analysis with the Waters® ACQUITY® TQD System (Figure 1) in combination with specialized software, ProfileLynx™ and QuanOptimize™ Application Managers, is the ideal choice for quantitation of a solubility screen.



Figure 1. ACQUITY TQD System.

EXPERIMENTAL

A set of 23 commercially available compounds were randomly chosen to demonstrate the ProfileLynx Application Manager.

Samples

Individual stock solutions of the 23-compound library were prepared in a 96-well plate at a concentration of 5 mM in dimethylsulfoxide (DMSO). The three different pH buffer solutions were prepared in the following manner:

- pH 1.0 - A solution of hydrochloric acid (HCl) was prepared at approximately 0.1 M and adjusted to pH 1.0 with either additional HCl or water.
- pH 7.4 - A solution of phosphate buffered saline (PBS, pH~7) was pH adjusted to 7.4 with ammonium hydroxide.
- pH 9.4 - A solution of PBS was pH adjusted to 9.4 with ammonium hydroxide.

For each different pH assay, 50 µL of each 5 mM stock solution was transferred to a 2-mL, 96-well plate. 950 µL of the appropriate pH buffer was added to each well in the plate resulting in compound concentrations of 250 µM.

[APPLICATION NOTE]

The plate was shaken gently on a shaker for 1.5 hours at room temperature. The well contents were transferred to a Sirocco™ plate and were vacuum-filtered for ~30 to 60 seconds into a collection plate.

The sample/pH buffer solutions were diluted 1:100 in 50:50 acetonitrile/water, resulting in sample concentrations of a maximum of 2.5 μM (assuming that the compound was completely soluble at 250 μM in pH buffer). Samples were injected (5 μL injections) at this concentration.

Standards

A three-point calibration of standards was used for quantitation of the sample solutions. Standards were prepared at concentrations of 0.25 μM , 1.25 μM , and 2.5 μM . 5 mM stock solutions of the compounds in DMSO were diluted 1:100 in 50:50 acetonitrile/water to a concentration of 50 μM .

The 50 μM stock solutions were diluted 1:20 in 50:50 acetonitrile/water resulting in the 2.5 μM standard solutions. The 2.5 μM standard solutions were diluted 1:10 to give 0.25 μM standard solutions, which were then diluted 1:2 to give 1.25 μM standard solutions.

These samples and standards were analyzed by UPLC/MS/MS. The QuanOptimize Application Manager was used for the automated optimization of the MS multiple reaction monitoring (MRM) conditions for each compound.

LC conditions

LC system: Waters ACQUITY TQD System
Column: ACQUITY UPLC® BEH C₁₈ Column
2.1 x 50 mm, 1.7 μm
Column temp: 40 °C
Flow rate: 600 $\mu\text{L}/\text{min}$
Mobile phase A: 0.1% Formic acid in water
Mobile phase B: 0.1% Formic acid in acetonitrile
Gradient: 5 to 95% B/1.3 min

MS conditions

MS system: Waters TQ Detector
Ionization mode: ESI Positive
Capillary voltage: 3200 V
Source temp: 150 °C
Desolvation temp: 450 °C
Desolvation gas: 900 L/hr
Cone gas flow: 50 L/hr
Inter-scan delay: 20 ms
Inter-channel delay: 5 ms
Dwell: 200 ms
Acquisition range: 100 to 1000 m/z

Calculations

Because the solubility assay of the compounds is carried out at 250 μM and the samples are diluted 1:100 before UPLC analysis, the concentrations determined by UPLC/MS/MS must be multiplied by a factor of 100 to get the final solubility. If this final measured concentration is 250 μM , then the compound has a solubility greater than or equal to 250 μM at the pH of the buffer.




Figure 2. Flowchart of solubility assay procedure.

DISCUSSION

Solubility was determined using MassLynx™ Software's ProfileLynx Application Manager. Each compound was identified within the sample list and the sample type (standard or analyte) was specified. The solubility concentration of the analytes was determined using a calibration curve generated by a concentration series of each standard.

Any solubility values outside of a specified minimum and maximum range were automatically flagged within the ProfileLynx Results Browser (Figure 3). For this experiment, the minimum was set at 0.0 mg/mL and the maximum at 2.5 mg/mL.

The interactive browser allowed for the editing of peak integration. Peak assignments were easily changed and peak integrations were quickly optimized. Results were then exported in a format amenable to the corporate database.

The data in Figure 3 show a typical solubility result. The solubility of Oxybutynin is nearly 10-fold lower at high pH than at low pH. Table 1 summarizes the solubility results for all 23 compounds tested.

In addition to determining any pH effects on the solubility of the various compounds, this assay will ensure that all samples have sufficient solubility to remain in solution under the conditions used for subsequent ADME assays.

All of the compounds exhibited high solubility such that the measured apparent solubility was greater than 250 μM for all samples. If the actual intrinsic solubility for these compounds is required, an equilibrium solubility assay using saturated solutions at an appropriate pH should be employed to ensure the compounds are not ionized.




Figure 3. Results for Oxybutynin displayed in the ProfileLynx browser.

COMPOUND	BUFFER	Injection μ M SOLUBILITY	Final μ M SOLUBILITY	COMPOUND	BUFFER	Injection μ M SOLUBILITY	Final μ M SOLUBILITY
Alprenolol	pH 1.5	17.436	>250 μ M	Nortriptyline	pH 1.5	15.576	>250 μ M
Alprenolol	pH 7.4	16.776	>250 μ M	Nortriptyline	pH 7.4	13.873	>250 μ M
Alprenolol	pH 9.4	14.826	>250 μ M	Nortriptyline	pH 9.4	11.548	>250 μ M
Amitriptyline	pH 1.5	15.581	>250 μ M	Oxprenolol	pH 1.5	14.377	>250 μ M
Amitriptyline	pH 7.4	13.282	>250 μ M	Oxprenolol	pH 7.4	13.618	>250 μ M
Amitriptyline	pH 9.4	6.923	>250 μ M	Oxprenolol	pH 9.4	13.151	>250 μ M
Betaxolol	pH 1.5	16.771	>250 μ M	Oxybutynin	pH 1.5	13.889	>250 μ M
Betaxolol	pH 7.4	16.611	>250 μ M	Oxybutynin	pH 7.4	10.329	>250 μ M
Betaxolol	pH 9.4	14.406	>250 μ M	Oxybutynin	pH 9.4	2.891	>250 μ M
Caffeine	pH 1.5	12.989	>250 μ M	Pindolol	pH 1.5	11.423	>250 μ M
Caffeine	pH 7.4	14.25	>250 μ M	Pindolol	pH 7.4	11.093	>250 μ M
Caffeine	pH 9.4	12.955	>250 μ M	Pindolol	pH 9.4	10.726	>250 μ M
Colchicine	pH 1.5	16.051	>250 μ M	Propranolol	pH 1.5	13.158	>250 μ M
Colchicine	pH 7.4	16.838	>250 μ M	Propranolol	pH 7.4	12.264	>250 μ M
Colchicine	pH 9.4	15.842	>250 μ M	Propranolol	pH 9.4	11.249	>250 μ M
Diltiazem	pH 1.5	15.738	>250 μ M	Sulfadimethoxine	pH 1.5	14.94	>250 μ M
Diltiazem	pH 7.4	14.309	>250 μ M	Sulfadimethoxine	pH 7.4	15.426	>250 μ M
Diltiazem	pH 9.4	12.692	>250 μ M	Sulfadimethoxine	pH 9.4	15.272	>250 μ M
Diphenylamine	pH 1.5	22.981	>250 μ M	Timolol	pH 1.5	15.618	>250 μ M
Diphenylamine	pH 7.4	16.101	>250 μ M	Timolol	pH 7.4	14.44	>250 μ M
Diphenylamine	pH 9.4	17.7	>250 μ M	Timolol	pH 9.4	13.529	>250 μ M
Doxepin	pH 1.5	15.492	>250 μ M	Tolazamide	pH 1.5	8.985	>250 μ M
Doxepin	pH 7.4	13.986	>250 μ M	Tolazamide	pH 7.4	18.217	>250 μ M
Doxepin	pH 9.4	10.82	>250 μ M	Tolazamide	pH 9.4	13.894	>250 μ M
Lidocaine	pH 1.5	14.352	>250 μ M	Tolbutamide	pH 1.5	24.375	>250 μ M
Lidocaine	pH 7.4	13.519	>250 μ M	Tolbutamide	pH 7.4	28.877	>250 μ M
Lidocaine	pH 9.4	13.078	>250 μ M	Tolbutamide	pH 9.4	27.486	>250 μ M
Loperamide	pH 1.5	13.344	>250 μ M	Verapamil	pH 1.5	13.956	>250 μ M
Loperamide	pH 7.4	10.836	>250 μ M	Verapamil	pH 7.4	13.072	>250 μ M
Loperamide	pH 9.4	---	---	Verapamil	pH 9.4	9.151	>250 μ M
Metoprolol	pH 1.5	14.818	>250 μ M	Zolpidem	pH 1.5	14.657	>250 μ M
Metoprolol	pH 7.4	13.77	>250 μ M	Zolpidem	pH 7.4	13.656	>250 μ M
Metoprolol	pH 9.4	13.183	>250 μ M	Zolpidem	pH 9.4	13.113	>250 μ M
Nephazoline	pH 1.5	14.035	>250 μ M				
Nephazoline	pH 7.4	12.724	>250 μ M				
Nephazoline	pH 9.4	12.903	>250 μ M				

Table 1: Summary of Solubility Data

CONCLUSION

The 23 compounds were analyzed with a UPLC/MS/MS protocol including MS multiple reaction monitoring (MRM) parameter optimization, MS acquisition method creation, data acquisition, data processing, and report generation.

Data generated from the variety of assays were all automatically processed with the same software. A single report was created for the 23 compounds containing the solubility results, enabling the researcher to analyze results quickly, thus increasing laboratory throughput. Results are displayed in an interactive, graphical summary format based on sample or experiment.

Using the method outlined here, compounds can be quickly and easily screened for solubility. MS detection ensures that the correct compound is being analyzed, while UPLC separation allows for the analysis of impure samples.

The results from this screening can then be used to determine those candidates with solubility levels consistent with the bioavailability levels needed to proceed down the development pipeline.

Using ProfileLynx and QuanOptimize Application Managers allowed for:

- Automated MS method development and data acquisition
- Single approach for data processing and report generation from multiple assays
- Complete automated analysis, processing, and reporting
- Increased laboratory throughput

Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Waters, ACQUITY, ACQUITY UPLC, UltraPerformance LC, and UPLC are registered trademarks of Waters Corporation. ProfileLynx, QuanOptimize, and The Science of What's Possible are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2008 Waters Corporation. Produced in the U.S.A.
May 2008. 720002612en AG-PDF



Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com

